Kiniwa et al. conducted a clinical study on liquid biopsies from melanoma patients undergoing combined treatment with BRAF/MEK inhibitors, demonstrating the presence of CTCs even in the early stages of melanoma. This evidence concerns the gene MAP2K7 and melanoma.